Pay in 4 interest-free payments of $6.93 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
With compounded GLP-1 medications available at a fraction of the cost of brand-name alternatives, MEDVi eliminates the financial barriers that often prevent patients from accessing effective weight loss therapy
Orforglipron Pending Approval - An experimental oral GLP-1 receptor agonist in clinical trials
A number of telehealth companies now offer the option to access these medications without ever leaving your home
Retatrutide: GLP-1 + GIP + Glucagon (Triple Agonist) Retatrutide (LY3437943) keeps the same two receptors as tirzepatide, then adds a third: glucagon
HFpEF and Obesity and Recent or Recurrent Hospitalisation Patients with HFpEF, obesity and a history of recent HF decompensation (within the preceding 12 months) constituted a significant proportion of the populations in the STEP-HFpEF and SUMMIT trials
US$ 20.34
US$ 20.90
US$ 27.06
US$ 24.13
US$ 23.34
US$ 29.07
